| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(5 months from now) | |
| US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
| US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
Uloric is owned by Takeda Pharms Usa.
Uloric contains Febuxostat.
Uloric has a total of 3 drug patents out of which 0 drug patents have expired.
Uloric was authorised for market use on 13 February, 2009.
Uloric is available in tablet;oral dosage forms.
Uloric can be used as use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline.
The generics of Uloric are possible to be released after 08 September, 2031.
Drugs and Companies using FEBUXOSTAT ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline
Dosage: TABLET;ORAL
ULORIC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic